Viracta Therapeutics to Present at Upcoming Investor Conferences in September
Viracta Therapeutics, a precision oncology firm focusing on virus-associated malignancies, will present at multiple upcoming investor conferences. The H.C. Wainwright 23rd Annual Global Investment Conference will feature an on-demand presentation available from September 13, 2021. Following this, Viracta will participate in the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit on September 21, 2021, at 4:35 PM ET, and the 2021 Cantor Virtual Global Healthcare Conference on September 30, 2021, at 8:40 AM ET. Details and webcasts are accessible through their investor relations website.
- None.
- None.
SAN DIEGO, Sept. 7, 2021 /PRNewswire/ -- Viracta Therapeutics, Inc. (NASDAQ: VIRX), a precision oncology company targeting virus-associated malignancies, today announced that company management will present and be available for virtual one-on-one meetings at the H.C. Wainwright 23rd Annual Global Investment Conference, September 13 – 15, 2021, the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit, September 20 – 23, 2021, and the 2021 Cantor Virtual Global Healthcare Conference, September 27 – 30, 2021.
Details on the presentations can be found below.
H.C. Wainwright 23rd Annual Global Investment Conference | |
Presentation Date: | Corporate presentation will be available on-demand to conference |
Oppenheimer Fall Healthcare Life Sciences & MedTech Summit | |
Presentation Date: | September 21, 2021 |
Presentation Time: | 4:35 PM ET |
Format: | Corporate presentation |
Webcast Link: | |
2021 Cantor Virtual Global Healthcare Conference | |
Presentation Date: | September 30, 2021 |
Presentation Time: | 8:40 AM ET |
Format: | Corporate presentation |
A replay of the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit presentation will be available on the "Events and Webcasts" section of the Viracta website at https://viracta.investorroom.com/events-and-webcasts.
About Viracta Therapeutics, Inc.
Viracta is a precision oncology company targeting virus-associated malignancies. Viracta's proprietary investigational drug, nanatinostat, is currently being evaluated in combination with the antiviral agent valganciclovir as an oral combination therapy in two Phase 2 clinical trials for EBV-positive lymphoma. Viracta is also pursuing application of its inducible synthetic lethality approach in other EBV-associated malignancies, such as nasopharyngeal carcinoma, gastric carcinoma, and other virus-related cancers.
For additional information please visit www.viracta.com.
Investor Relations Contact: | Company Contact: |
Joyce Allaire | Dan Chevallard |
LifeSci Advisors | Chief Operating Officer and Chief Financial Officer |
(212) 915-2569 | (858) 771-4193 |
View original content to download multimedia:https://www.prnewswire.com/news-releases/viracta-therapeutics-to-present-at-upcoming-investor-conferences-in-september-301370207.html
SOURCE Viracta
FAQ
What presentations will Viracta Therapeutics make in September 2021?
When is Viracta's presentation at the Oppenheimer Fall Healthcare Life Sciences Summit?
How can I access the webcasts of Viracta's presentations?
What is the focus of Viracta Therapeutics?
What is the ticker symbol for Viracta Therapeutics?
